Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852755 | 0.84 | NOTUM (0.57) | GPR119ESRRACA1CA2CA9 | |
| SCHEMBL26569707 | 0.82 | ACKR3 (0.47) | GPR119ESRRACA1CA2CA9 | |
| SCHEMBL3477570 | 0.82 | CA1 (0.57) | ESRRACA1CA2CA9CA12 | |
| SCHEMBL27877288 | 0.80 | ESRRA (0.57) | ESRRACA1CA2CA9CA4 | |
| SCHEMBL69876 | 0.80 | ESRRA (0.62) | ESRRACA1CA2CA9CA4 | |
| SCHEMBL16246067 | 0.79 | GPR119 (0.42) | GPR119ESRRACA1CA2CA9 | |
| SCHEMBL11902351 | 0.79 | CA1 (0.57) | ESRRACA1CA2CA9CA4 | |
| SCHEMBL2330243 | 0.79 | CA1 (0.57) | ESRRACA1CA2CA9CA12 | |
| SCHEMBL28801446 | 0.78 | ESRRA (0.60) | ESRRACA1CA2CA9CA4 | |
| SCHEMBL14532856 | 0.78 | S1PR1 (0.50) | ESRRACA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102946882-B | Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators | ARGUSINA, INC. (US) | 2016-05-18 | — | — | CN | disclosed |
| WO-2014181287-A1 | HETEROCYCLYL COMPOUNDS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2014-11-13 | — | — | WO | disclosed |
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| CN-102946882-A | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators | ARGUSINA INC | 2013-02-27 | — | — | CN | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | GPR119 3/4885ESRRA 582/4885CA1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.